Preparation of anti-canine interleukin-31 receptor alpha polyclonal antibody and evaluation of its therapeutic effect in canine atopic dermatitis

Springer Science and Business Media LLC
Qiuhua Li1, Yanyan Qu1, Yao Li1, Xi Ma1, Mingxing Ding1, Yi Ding1
1College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China

Tóm tắt

AbstractCanine atopic dermatitis (CAD) is a prevalent genetically susceptible inflammatory and pruritic allergic skin condition affecting not only the health of dogs but also the quality of life of their owners. Interleukin-31 (IL-31) and interleukin-31 receptor alpha (IL-31RA) are essential for the development of pruritus in primates and mice. Hence, it is expected that inhibiting IL-31RA will be an effective approach to alleviate pruritus. The purpose of the study was to produce anti-canine IL-31RA polyclonal antibodies (anti-IL-31RA pAbs) and evaluate their efficacy in inhibiting house dust mite (HDM)-evoked pruritic responses. Dogs were immunized with antigens formed by IL-31RA recombinant short peptides coupled to BSA to produce anti-IL-31RA pAbs. The CAD model was developed by using HDM allergen stimulation, and the effects of IL-31RA pAbs on the reduction of pruritus in CAD model dogs were examined. The Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4 and pruritus Visual Analog Scale (pVAS) were utilized to evaluate pruritic responses, and skin tissue samples were collected from the inguinal area for pathological assessment of skin inflammatory cell infiltration. The results showed that anti-IL-31RA pAbs with high titers (1:128,000) and specificity were effectively produced. In the CAD model group, the severity of skin damage, pruritus score, inflammatory cell infiltration and level of inflammatory factors were considerably elevated. Anti-IL-31RA pAbs relieved pruritic behavior and dermatitis in dogs compared to placebo-treated dogs. In conclusion, anti-IL-31RA pAbs effectively suppressed CAD in vivo and are anticipated to be an effective novel treatment for pruritic skin disorders such as CAD.

Từ khóa


Tài liệu tham khảo

Arai, I., M. Tsuji, H. Takeda, N. Akiyama, and S. Saito. 2013. A single dose of interleukin-31 (IL-31) causes continuous itch-associated scratching behavior in mice. Experimental Dermatology 22 (10): 669–671. https://doi.org/10.1111/exd.12222.

Bağci, I.S., and T. Ruzicka. 2018. IL-31: A new key player in dermatology and beyond. The Journal of Allergy and Clinical Immunology 141 (3): 858–866. https://doi.org/10.1016/j.jaci.2017.10.045.

Bilsborough, J., D.Y. Leung, M. Maurer, M. Howell, M. Boguniewicz, L. Yao, H. Story, C. Leciel, B. Harder, and J.A. Gross. 2006. IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis. The Journal of Allergy and Clinical Immunology 117 (2): 418–425. https://doi.org/10.1016/j.jaci.2005.10.046.

Boguniewicz, M. 2017. Biologic therapy for atopic dermatitis: Moving beyond the practice parameter and guidelines. The Journal of Allergy and Clinical Immunology: In Practice 5 (6): 1477–1487. https://doi.org/10.1016/j.jaip.2017.08.031.

Bradley, C.W., D.O. Morris, S.C. Rankin, C.L. Cain, A.M. Misic, T. Houser, E.A. Mauldin, and E.A. Grice. 2016. Longitudinal evaluation of the skin microbiome and association with microenvironment and treatment in canine atopic dermatitis. The Journal of Investigative Dermatology 136 (6): 1182–1190. https://doi.org/10.1016/j.jid.2016.01.023.

Brunner, P.M., E. Guttman-Yassky, and D.Y. Leung. 2017. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. The Journal of Allergy and Clinical Immunology 139 (4s): S65–s76. https://doi.org/10.1016/j.jaci.2017.01.011.

Cevikbas, F., X. Wang, T. Akiyama, C. Kempkes, T. Savinko, A. Antal, G. Kukova, T. Buhl, A. Ikoma, and J. Buddenkotte, et al. 2014. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. The Journal of Allergy and Clinical Immunology 133 (2): 448–460. https://doi.org/10.1016/j.jaci.2013.10.048.

Chun, P.I.F., and H. Lehman. 2020. Current and future monoclonal antibodies in the treatment of atopic dermatitis. Clinical Reviews in Allergy and Immunology 59 (2): 208–219. https://doi.org/10.1007/s12016-020-08802-9.

Czarnowicki, T., H. Esaki, J. Gonzalez, D. Malajian, A. Shemer, S. Noda, S. Talasila, A. Berry, J. Gray, and L. Becker, et al. 2015. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. The Journal of Allergy and Clinical Immunology 136 (4): 941–951.e943. https://doi.org/10.1016/j.jaci.2015.05.049.

Datsi, A., M. Steinhoff, F. Ahmad, M. Alam, and J. Buddenkotte. 2021. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy 76 (10): 2982–2997. https://doi.org/10.1111/all.14791.

Dillon, S.R., C. Sprecher, A. Hammond, J. Bilsborough, M. Rosenfeld-Franklin, S.R. Presnell, H.S. Haugen, M. Maurer, B. Harder, and J. Johnston, et al. 2004. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nature Immunology 5 (7): 752–760. https://doi.org/10.1038/ni1084.

Fan, H.J., X.S. Zhao, Z.B. Tan, B. Liu, H.L. Xu, Y.T. Wu, L.P. Xie, Y.M. Bi, Y.G. Lai, H.F. Liang, and Y.C. Zhou. 2019. Effects and mechanism of action of Huang-Lian-Jie-Du-Tang in atopic dermatitis-like skin dysfunction in vivo and in vitro. Journal of Ethnopharmacology 240: 111937. https://doi.org/10.1016/j.jep.2019.111937.

Frazier, W., and N. Bhardwaj. 2020. Atopic Dermatitis: Diagnosis and Treatment. American Family Physician 101 (10): 590–598.

Gadeyne, C., P. Little, V.L. King, N. Edwards, K. Davis, and M.R. Stegemann. 2014. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia. Veterinary Dermatology 25 (6): 512–518.e586. https://doi.org/10.1111/vde.12166.

Gedon, N.K.Y., and R.S. Mueller. 2018. Atopic dermatitis in cats and dogs: A difficult disease for animals and owners. Clinical and Translational Allergy 8: 41. https://doi.org/10.1186/s13601-018-0228-5.

Grimstad, O., Y. Sawanobori, C. Vestergaard, J. Bilsborough, U.B. Olsen, C. Grønhøj-Larsen, and K. Matsushima. 2009. Anti-interleukin-31-antibodies ameliorate scratching behavior in NC/Nga mice: A model of atopic dermatitis. Experimental Dermatology 18 (1): 35–43. https://doi.org/10.1111/j.1600-0625.2008.00766.x.

Hamann, C.R., and J.P. Thyssen. 2018. Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis. Journal of the American Academy of Dermatology 78 (3 Suppl 1): S37–s42. https://doi.org/10.1016/j.jaad.2017.12.018.

Hansson, L., A. Bäckman, A. Ny, M. Edlund, E. Ekholm, B. Ekstrand Hammarström, J. Törnell, P. Wallbrandt, H. Wennbo, and T. Egelrud. 2002. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: A model for chronic itchy dermatitis. The Journal of Investigative Dermatology 118 (3): 444–449. https://doi.org/10.1046/j.0022-202x.2001.01684.x.

Hawro, T., R. Saluja, K. Weller, S. Altrichter, M. Metz, and M. Maurer. 2014. Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. Allergy 69 (1): 113–117. https://doi.org/10.1111/all.12316.

Hill, P.B., P. Lau, and J. Rybnicek. 2007. Development of an owner-assessed scale to measure the severity of pruritus in dogs. Veterinary Dermatology 18 (5): 301–308. https://doi.org/10.1111/j.1365-3164.2007.00616.x.

Hillier, A., and C.E. Griffin. 2001. The ACVD task force on canine atopic dermatitis (I): Incidence and prevalence. Veterinary Immunology and Immunopathology 81 (3–4): 147–151. https://doi.org/10.1016/s0165-2427(01)00296-3.

Huang, C.H., I.C. Kuo, H. Xu, Y.S. Lee, and K.Y. Chua. 2003. Mite allergen induces allergic dermatitis with concomitant neurogenic inflammation in mouse. The Journal of Investigative Dermatology 121 (2): 289–293. https://doi.org/10.1046/j.1523-1747.2003.12356.x.

Kasutani, K., E. Fujii, S. Ohyama, H. Adachi, M. Hasegawa, H. Kitamura, and N. Yamashita. 2014. Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice. British Journal of Pharmacology 171 (22): 5049–5058. https://doi.org/10.1111/bph.12823.

Koblenzer, C.S. 1999. Itching and the atopic skin. The Journal of Allergy and Clinical Immunology 104 (3 Pt 2): S109–113. https://doi.org/10.1016/s0091-6749(99)70052-7.

Kuzumi, A., A. Yoshizaki, K.M. Matsuda, H. Kotani, Y. Norimatsu, M. Fukayama, S. Ebata, T. Fukasawa, A. Yoshizaki-Ogawa, Y. Asano, et al. 2021. Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nature Communications 12 (1): 5947. https://doi.org/10.1038/s41467-021-26099-w.

Lee, Y.S., S.B. Han, H.J. Ham, J.H. Park, J.S. Lee, D.Y. Hwang, Y.S. Jung, D.Y. Yoon, and J.T. Hong. 2020. IL-32γ suppressed atopic dermatitis through inhibition of miR-205 expression via inactivation of nuclear factor-kappa B. The Journal of Allergy and Clinical Immunology 146 (1): 156–168. https://doi.org/10.1016/j.jaci.2019.12.905.

Leung, D.Y., N. Jain, and H.L. Leo. 2003. New concepts in the pathogenesis of atopic dermatitis. Current Opinion in Immunology 15 (6): 634–638. https://doi.org/10.1016/j.coi.2003.09.009.

Lewis, K.E., M.S. Holdren, M.F. Maurer, S. Underwood, B. Meengs, S.H. Julien, K.A. Byrnes-Blake, J.A. Freeman, T.R. Bukowski, A.C. Wolf, N.B. Hamacher, M.W. Rixon, and S.R. Dillon. 2017. Interleukin (IL) 31 induces in cynomolgus monkeys a rapid and intense itch response that can be inhibited by an IL-31 neutralizing antibody. Journal of the European Academy of Dermatology and Venereology 31 (1): 142–150. https://doi.org/10.1111/jdv.13794.

Marsella, R., and M.N. Saridomichelakis. 2010. Environmental and oral challenge with storage mites in beagles experimentally sensitized to Dermatophagoides farinae. Veterinary Dermatology 21 (1): 105–111. https://doi.org/10.1111/j.1365-3164.2009.00859.x.

Marsella, R., T. Olivry, C. Nicklin, and J. Lopez. 2006. Pilot investigation of a model for canine atopic dermatitis: Environmental house dust mite challenge of high-IgE-producing beagles, mite hypersensitive dogs with atopic dermatitis and normal dogs. Veterinary Dermatology 17 (1): 24–35. https://doi.org/10.1111/j.1365-3164.2005.00496.x.

Matsuda, H., N. Watanabe, G.P. Geba, J. Sperl, M. Tsudzuki, J. Hiroi, M. Matsumoto, H. Ushio, S. Saito, P.W. Askenase, and C. Ra. 1997. Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. International Immunology 9 (3): 461–466. https://doi.org/10.1093/intimm/9.3.461.

Olivry, T., M. Saridomichelakis, T. Nuttall, E. Bensignor, C.E. Griffin, and P.B. Hill. 2014. Validation of the Canine Atopic Dermatitis Extent and Severity Index (CADESI)-4, a simplified severity scale for assessing skin lesions of atopic dermatitis in dogs. Veterinary Dermatology 25 (2): 77–85.e25. https://doi.org/10.1111/vde.12107.

Patrizi, A., B. Raone, and G.M. Ravaioli. 2015. Management of atopic dermatitis: Safety and efficacy of phototherapy. Clinical, Cosmetic and Investigational Dermatology 8: 511–520. https://doi.org/10.2147/ccid.S87987.

Pierezan, F., T. Olivry, J.S. Paps, S.D. Lawhon, J. Wu, J.M. Steiner, J.S. Suchodolski, and A. Rodrigues Hoffmann. 2016. The skin microbiome in allergen-induced canine atopic dermatitis. Veterinary Dermatology 27 (5): 332–e382. https://doi.org/10.1111/vde.12366.

Pucheu-Haston, C.M., H.A. Jackson, T. Olivry, S.M. Dunston, and B. Hammerberg. 2008. Epicutaneous sensitization with Dermatophagoides farinae induces generalized allergic dermatitis and elevated mite-specific immunoglobulin E levels in a canine model of atopic dermatitis. Clinical and Experimental Allergy 38 (4): 667–679. https://doi.org/10.1111/j.1365-2222.2008.02949.x.

Raap, U., M. Gehring, S. Kleiner, U. Rüdrich, B. Eiz-Vesper, H. Haas, A. Kapp, and B.F. Gibbs. 2017. Human basophils are a source of - and are differentially activated by - IL-31. Clinical and Experimental Allergy 47 (4): 499–508. https://doi.org/10.1111/cea.12875.

Ratchataswan, T., T.M. Banzon, J.P. Thyssen, S. Weidinger, E. Guttman-Yassky, and W. Phipatanakul. 2021. Biologics for treatment of atopic dermatitis: Current status and future prospect. The Journal of Allergy and Clinical Immunology: In Practice 9 (3): 1053–1065. https://doi.org/10.1016/j.jaip.2020.11.034.

Suzuki, T., K. Nishiyama, K. Kawata, K. Sugimoto, M. Isome, S. Suzuki, R. Nozawa, Y. Ichikawa, Y. Watanabe, and T. Suzutani. 2020. Effect of the Lactococcus Lactis 11/19-B1 Strain on atopic dermatitis in a clinical test and mouse model. Nutrients 12 (3): 763. https://doi.org/10.3390/nu12030763.

Thaçi, D., E.L. Simpson, M. Deleuran, Y. Kataoka, Z. Chen, A. Gadkari, L. Eckert, B. Akinlade, N.M.H. Graham, G. Pirozzi, and M. Ardeleanu. 2019. Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). Journal of Dermatological Science 94 (2): 266–275. https://doi.org/10.1016/j.jdermsci.2019.02.002.

Zhang, Q., P. Putheti, Q. Zhou, Q. Liu, and W. Gao. 2008. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine & Growth Factor Reviews 19 (5–6): 347–356. https://doi.org/10.1016/j.cytogfr.2008.08.003.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Thông tin tác giả